Thomas W. Burns is the Chairman and Chief Executive Officer at Glaukos Corporation, a leading ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. With over three decades of experience in the healthcare industry, Burns has been instrumental in guiding Glaukos to its current position as a pioneer in the field of ophthalmic innovation. Before joining Glaukos, Burns held various leadership positions in the medical device and pharmaceutical sectors. He began his career at Allergan, Inc., where he spent 25 years in roles of increasing responsibility, ultimately serving as the President of Allergan's North American and Latin American businesses. During his tenure at Allergan, Burns played a key role in the development and launch of several successful ophthalmic products, including the blockbuster drug, Botox. His strategic vision and operational expertise were crucial in driving Allergan's growth and establishing the company as a global leader in the ophthalmic industry. As Chairman and CEO of Glaukos, Burns has been at the forefront of the company's efforts to develop and commercialize groundbreaking therapies for patients suffering from debilitating eye diseases. Under his leadership, Glaukos has successfully introduced several innovative products, such as the iStent, the first and only FDA-approved micro-invasive glaucoma surgery (MIGS) device. Burns' unwavering commitment to improving patient outcomes and his ability to foster a culture of innovation have been pivotal in positioning Glaukos as a trailblazer in the ophthalmic industry. With his extensive experience and strategic guidance, Burns continues to steer Glaukos towards its mission of transforming the treatment landscape for patients worldwide.